

Nancy A. Dreyer

Email: ndreyer@dreyerstrategies.com

www.dreyerstrategies.com

Professional Experience

Dreyer Strategies LLC	2022-
IQVIA Real-World Solutions	
Chief Scientific Officer Emerita	2022-2023
Chief Scientific Officer	2018-2022
Head, Center for Advanced Evidence Generation	2016-2022
Senior Vice President & Global Chief of Scientific Affairs	2016-2022
Quintiles (merged with IMS Health to become IQVIA in 2016)	
Senior Vice President & Global Chief of Scientific Affairs	2011-2016
University of North Carolina at Chapel Hill	
Adjunct Professor of Epidemiology	2013-
Outcome Sciences Inc. (acquired by Quintiles in 2011)	
Senior Vice President & Global Chief of Scientific Affairs	2005-2011
I3 Research (formerly Ingenix, now Optum), United Health Group	
Senior Vice President	1999-2005
Epidemiology Resources Inc & the New England Epidemiology Institute	1980-1999
CEO, President & Founder	1980-1999
Founder and Publisher of peer reviewed journal, Epidemiology	1990-1999

Advisory Boards, Professional Honors and Awards

Current Board Memberships & Other Leadership Positions

- Brandeis University Trustee, 2019-
- Drug Information Association: Director 2012-2015, Scientific and Policy Advisory Council, 2018-
- Duke-Margolis Center for Health Policy Research, Member, RWE Collaborative Advisory Group, 2017-
- Global Cardiovascular Clinical Trials Forum 2024 Scientific Program Planning Committee, 2024-
- International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Real-World Data Steering Committee, 2021-

Recognition and Awards

- PharmaVoice Red Jacket Award in 2019 for sustained inspirational leadership in the life sciences. Twice recognized as one of the 100 most inspiring people in life sciences (2007, 2014)
- DIA Global Inspire Award for Author of the Year for “Advancing a framework for regulatory use of real-world evidence: When real is reliable.” 2019
- Fellow of the Drug Information Association (FDIA), 2017
- Fellow, International Society for Pharmacoepidemiology (FISPE), 2003

Selected recent keynote / high-profile speaking engagements

- Gilead, Grand Rounds, 2020, Methods and Innovation Conference, 2024,2025
- Pfizer, Latin America Oncology Forum, Panama City, Panama, 2023
- Korea Institute of Drug Safety and Risk Management, 2023
- Honored Invited Speaker, Harry Guess Memorial Lecture, University of North Carolina, 2023
- 1st Boao International Conference on Real-World Studies of Medical Products, Hainan Province, China, December 2022
- Asia Pacific Oncology Drug Development Consortium, September 2022
- American Statistical Association Biopharmaceutical Section Regulatory-Industry Statistics Workshop, Keynote on Real-World Evidence with FDA, September 2022
- Amgen, Keynote address on using RWE for regulatory and other purposes, 2022
- Advanced Oncology RWE programs in America – Lessons for Europe. Precision Oncology Symposium, Paris, France, 2021
- Astellas Global Medical Affairs Summit, 2021
- Boehringer-Ingelheim, Global Summit, 2020
- Takeda with Mark McClellan, former FDA Commissioner, 2020
- AbbVie Real-World Evidence Panel, 2019
- Lilly EXPERT Advisory Panel, 2019
- National Academy of Science, Medicine and Engineering Forum on Drug Discovery, Development, and Translation: Examining the Impact of RWE on Medical Product Development: A Workshop Series, 2018

Education

University of North Carolina at Chapel Hill: PhD and MPH with a concentration in Epidemiology
Brandeis University: AB

Publications

Books

Gliklich R, Dreyer N, Leavy M, eds. Registries for Evaluating Patient Outcomes: A User's Guide. Conducted under Contract No. 290 2014 00004-C.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014. 1st edition, 2007; 2nd Edition, 2010; Third edition, 2014. Also available in Korean (Korean National Evidence-based Healthcare Collaborating Agency, published December 2010), and in Chinese (University of Peking, published December 2012).

Gliklich RE, Leavy MB, Dreyer NA (sr eds). Registries for Evaluating Patient Outcomes: A User's Guide. 4th ed. (Prepared by L&M Policy Research, LLC, under Contract No. 290-2014-00004-C with partners OM1 and IQVIA) AHRQ Publication No. 19(20)-EHC020. Rockville, MD: Agency for Healthcare Research and Quality; September 2020. Posted final reports are located on the Effective Health Care Program search page.
<https://effectivehealthcare.ahrq.gov/products/registries-guide-4th-edition/users-guide>.

Gliklich R, Dreyer N, Leavy M, eds. Tools and Technologies for Registry Interoperability. Registries for Evaluating Patient Outcomes: A User's Guide. Addendum 2. AHRQ Publication No. 19(20)-EHC017-EF, October 2019

Gliklich RE, Dreyer NA, Levy M, Christian JB (eds). 21st Century Patient Registries. Registries for Evaluating Patient Outcomes: A User's Guide. EBook Addendum to Third Edition. (Prepared by L&M Policy Research, LLC, with partners OM1 and QuintilesIMS under Contract No. HHS290201400004C.) AHRQ Publication No. 17(18)-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality. March, 2018

Velentgas P, Dreyer NA, Nourjah P, Smith SR, Torchia MM. Developing a protocol for observational comparative effectiveness research: A User's Guide. Conducted under Contract No. 290-2005-0035-I. AHRQ Publication No. 12(13)-EHC099. Rockville, MD: Agency for Healthcare Research and Quality. January 2013. Available in Chinese (University of Peking, published December 2018).

Published Articles and Book Chapters

1. Dreyer NA: Sex roles and delay behavior. **Journal of Chronic Disease** 1978; 31:493-495.
2. Dreyer NA, Pizzo SV: Blood coagulation and idiopathic thromboembolism in fertile women. **Contraception** 1980; 22(2):123-135.
3. Dreyer NA, Woods NF, James SA: ISRO: A scale for measuring sex role orientation in women. **Sex Roles** 1981; 7(2):173-182.
4. Pizzo SV, Lewis JG, Campbell EE, Dreyer NA: Fibrinolytic response and oral contraceptive-associated thromboembolism. **Contraception** 1981; 23(2):181-186.
5. Dreyer NA, Loughlin JE, Friedlander ER, *et al.*: Choosing populations for study of human health effects of low-dose ionizing radiation. **American Journal of Public Health** 1981;71(11):1247-1252.
6. Dreyer NA, Loughlin JE, Fahey FH, Harley N: The feasibility of epidemiologic studies of cancer in people residing near Rocky Flats. **Health Physics** 1982;42(1):65-68.
7. Walker AM, Dreyer NA, Friedlander ER, *et al.*: An independent analysis of the National Cancer Institute study on non-nutritive sweeteners and bladder cancer. **American Journal of Public Health** 1982;72(4):376-381, 1982.
8. Dreyer NA, Friedlander ER: Identifying the health risks from very low-dose sparsely ionizing radiation. **American Journal of Public Health** 1982; 72(6):585-588.
9. Dreyer NA, Friedlander ER: Response to I.D.J. Bross on low-dose radiation re: study challenged. **American Journal of Public Health** 1982; 72:1301.
10. Walker AW, Loughlin JE, Friedlander ER, Rothman KJ, Dreyer NA: Projections of asbestos-related disease, 1980-2009. **Journal of Occupational Medicine** 1983; 25(5):409-425.
11. Dreyer NA: Analgesic-associated nephropathy: Etiology or tautology? **Royal Society of Medicine Services International Congress and Symposium Series** 1985; 96:19-24.
12. Lanes SF, Poole C, Dreyer NA, Lanza L: Toxic shock syndrome, contraceptive methods and vaginitis. **American Journal of Obstetrics and Gynecology** 1986;154(5):989-991.
13. Walker AM, Feldstein ML, Dreyer NA, Lanza L: Gastrointestinal illness rates on passenger cruise ships, 1975-1978. **Travel Medicine International** 1986;4(3):120-124.
14. Lanes SF, Delzell E, Dreyer NA, Rothman KJ: Analgesics and kidney disease. **International Journal of Epidemiology** 1986; 15:454-455.
15. Dreyer NA, Loughlin JE, Lanes SF, Rothman KJ: Mortality among employees of a nuclear power company. **Journal of Occupational Medicine** 1988; 30:988-989.
16. Rothman KJ, Funch DP, Dreyer NA: Bromocriptine and puerperal seizures. **Epidemiology** 1990; 1(3):232-238.
17. Lanes SF, Cohen A, Rothman KJ, Dreyer NA, Soden KJ: Mortality of cellulose fiber production workers. **Scandinavian Journal of Work, Environment and Health** 1990; 16(4):247-51.
18. Wilkinson GS, Dreyer NA: Leukemia among nuclear workers with protracted exposure to low dose ionizing radiation. **Epidemiology** 1991; 2(4):305-309.
19. Dreyer NA: Ethical Forum: Publication Rights – A Case Study. **The Epidemiology Monitor** 1992; 13(3):4.
20. Maintaining Radiation Protection Records. National Council on Radiation Protection and Measurements, Scientific Committee 46-5, NCRP Report No. 114, November 30, 1992.
21. Poole C, Kavet R, Funch DP, Donelan K, Charry JM, Dreyer NA: Depression and headaches in relation to an alternating-current electric power transmission line. **American Journal of Epidemiology** 1993; 137:318-30.
22. Walker AW, Funch D, Dreyer NA, Tolman KG, Kremer JM, Alarcón GS, Lee RG, Weinblatt ME: Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. **Arthritis and Rheumatism** 1993; 36(3):329-335.
23. Funch D, Dreyer NA, Bassin LG, Crawley JA, Brickley MG, Walker AM: The validity of case reports in a pharmacoepidemiologic study. **Post Marketing Surveillance** 1993; 7:283-289.
24. Poole C, Dreyer NA, Satterfield MH, Levin LL, Rothman KJ: Kidney cancer among petroleum refinery workers. **Journal of Environmental Health Perspectives** 1993; 101(6):53-62.
25. Lanes SF, Rothman KJ, Dreyer NA, Soden KJ: Mortality update of cellulose fiber production workers. **Scandinavian Journal of Work, Environment & Health** 1993; 19:426-428.

26. Lanes SF, Rothman KJ, Dreyer NA, Soden KJ: Mortality among workers exposed to glycerol polyglycidyl ether. **American Journal of Industrial Medicine** 1994; 25(5):689-696.
27. Dreyer NA: An epidemiologic view of causation: How it differs from the legal. **Defense Counsel Journal** 1994; 61(1):40-44.
28. Lanza LL, Walker AM, Bortnichak EA, Dreyer NA: Peptic ulcer and gastrointestinal hemorrhage associated with NSAID use in patients under 65 years of age: a large health maintenance organization cohort study. **Archives of Internal Medicine** 1995; 155:1371-1377.
29. Lanza LL, Walker MA, Bortnichak EA, Gause DO, Dreyer NA: Incidence of symptomatic liver function abnormalities in a cohort of NSAID users. **Pharmacoepidemiology & Drug Safety** 1995; 4:231-237.
30. Lanza LL, Dreyer NA, Schultz N, Walker AM: Use of insurance claims in epidemiologic research: identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis and renal disease. **Pharmacoepidemiology & Drug Safety** 1995; 4:239-248.
31. Walker AM, Funch DP, Sulsky SI, Dreyer NA: Patient factors associated with strut fracture in Björk-Shiley 60° convexo-concave heart valves. **Circulation** 1995;92(11):3235-3239.
32. Walker AM, Funch DP, Sulsky SI, Dreyer NA: Manufacturing characteristics associated with strut fracture in Björk-Shiley 60° convexo-concave heart valves. **Journal of Heart Valve Disease** 1995;6(4):640-648.
33. Rothman KJ, Loughlin JE, Funch DP, Dreyer NA: Overall mortality of cellular telephone customers. **Epidemiology** 1996; 7:303-305.
34. Funch DP, Rothman KJ, Loughlin JE, Dreyer NA: Utility of telephone company records for epidemiologic studies of cellular telephones. **Epidemiology** 1996; 7:299-302.
35. Lanes SF, Birmann BM, Walker AM, Sheffer AL, Rosello RA, Lewis BE, Dreyer NA: Characterization of asthma management at Fallon Community Health Plan, 1988-1991. **Pharmacoeconomics** 1996;10(4):378-385.
36. Lanes SF, Sulsky S, Walker AM, Isen J, Grier CE, Lewis BE, Dreyer NA: A cost density analysis of benign prostatic hyperplasia. **Clinical Therapeutics** 1996; 18(5):993-1004.
37. Rothman KJ, Lanza L, Lal A, Peskin EG, Dreyer NA: Incidence of pelvic inflammatory disease among women treated for gonorrhea and chlamydia. **Pharmacoepidemiology & Drug Safety** 1996; 5(6):409-414.
38. Lanes SF, Lanza LL, Radensky PW, Yood YA, Meenan RF, Walker AM, Dreyer NA: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. **Arthritis and Rheumatism** 1997; 40(8):1475-1481.
39. Walker AM, Sznke P, Bianchi LA, Field LF, Sutherland LR, Dreyer NA: 5-aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. **American Journal of Gastroenterology** 1997; 92(5):816-820.
40. Loughlin JE, Dreyer NA: In defense of the Social Security Administration Death Master File. **Epidemiology** 1997; 8(6):690-691.
41. Loughlin JE, Rothman KR, Dreyer NA: Lymphatic and hematopoietic cancer mortality in a population attending school adjacent to styrene-butadiene facilities, 1963-1993. **Journal of Epidemiology and Community Health** 1999; 53:283-287.
42. Dreyer NA, Loughlin JE, Rothman KJ: Epidemiologic safety surveillance of cellular telephones in the U.S. **Radiation Protection Dosimetry** 1999; 83(1-2):159-163.
43. Walker AM, Sznke P, Weatherby LB, Dicker LW, Lanza LL, Loughlin JE, Yee CL, Dreyer NA: Evaluating the risk of serious cardiac side effects among cisapride users in the United Kingdom and Canada. **American Journal of Medicine** 1999; 107:356-362.
44. Maradit Kremers H, Funch DP, Robson RA, Nalesnik MA, Ebrahim S, Cecka MJ, Opelz G, Dreyer NA, Walker AM: A combination study design to examine mycophenolate mofetil (MMF) and PTLTD in renal transplant patients. **Pharmacoepidemiology & Drug Safety** 1999; 8:509-518.
45. Dreyer NA, Loughlin JE, Rothman KJ: Cause-specific mortality in cellular telephone users. **JAMA** 1999;282(19):1814-1816.
46. Dreyer NA: Accessing third party data for research: Trust me? Trust me not? **Pharmacoepidemiology and Drug Safety** 2001; 10:385-388.
47. Funch DP, Brady J, Ko HH, Dreyer NA, Walker AM: Methods and objectives of a large US multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. **Recent Results Cancer Research** 2002; 159:81-88.
48. Rothman KJ, Funch DP, Alfredson T, Brady J, Dreyer NA: Randomized Field trial of vaginal douching, Pelvic Inflammatory Disease, and Pregnancy. **Epidemiology** 2003; 14:340-348.

49. Dreyer NA: Relative risk and statistical significance: Epidemiology 101 for lawyers. **Defense Research Institute**, March 19, 2004
50. Dreyer, NA: Tap into a global community of care. Web-based registries for orphan diseases. **Good Clinical Practice Journal**, 17-19 December, 2005.
51. Dreyer NA, Bertagna M, Gliklich RE: Designing and assessing registries to evaluate the safety of medical products. **The Monitor**. Association of Clinical Trials Professionals 2007; 21(4):47-50.
52. Eljovich L, Dreyer NA, Van Den Bos J, Johnston SC: Under-treatment and outcomes of non-traumatic subarachnoid hemorrhage by hospital volume: A multi-state study. **Stroke** 2008; 39:536-536.
53. Dreyer NA, Sheth N, Trontell A, Gliklich RE: Good practices for handling adverse events detected through patient registries. **Drug Information Journal** 2008; 42(5):421-428.
54. Dreyer NA, Garner S: Registries for robust evidence. **JAMA** 2009; 302(7):790-791.
55. Dreyer NA, Schneeweiss S, McNeil B, Berger ML, Walker A, Ollendorf D, Gliklich RE: GRACE Principles: Recognizing high-quality observational studies of comparative effectiveness. **American Journal of Managed Care** 2010; 16(6):467-471.
56. Adisasmito W, Chan PKS, Lee N, Oner AF, Gasimov V, Aghayev F, Zaman M, Bamgboye E, Dogan N, Coker R, Starzyk K, Dreyer NA, Toovey S: Effectiveness of antiviral treatment in human influenza H5N1 infections: analysis from a global patient registry. **Journal of Infectious Disease** 2010; 202(8):1154–1160.
57. Dreyer NA, Tunis SR, Berger M, Ollendorf D, Mattox PW, Gliklich RE: Why observational studies should be among the tools used in comparative effectiveness research. **Health Affairs** 2010; 29(10): 1818-1825.
58. Setoguchi S, Shrank WH, Liu J, Lee JC, Saya U, Winkelmayer WC, Dreyer NA. Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors: Challenges in comparing effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors for hypertension in Medicare data. **Clinical Pharmacology & Therapeutics** 2011; 89(5):674-82.
59. Dreyer NA. Making observational studies count: shaping the future of comparative effectiveness research. **Epidemiology** 2011; 22(3):295-297.
60. Li Q, Glynn RJ, Dreyer NA, Liu J, Mogun H, Setoguchi S. Validity of Claims-based Definitions of Impaired Left Ventricular Systolic Function in Medicare Patients. **Pharmacoepidemiology and Drug Safety** 2011; 20(7); 700-708.
61. Zaman M, Toovey S, Dreyer NA. An extended review of human infection with influenza H5N1 virus in North West Frontier Province (NWFP), Pakistan in 2007. **Emerging Infectious Diseases** 2011; 17:1056-1059.
62. Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand, SL. Prospective observational studies to assess comparative effectiveness: ISPOR good research practices task force report. **Value in Health** 2012;15(2):217-30.
63. Gliklich R, Glennie J, Mattox PW, Graff JS, Garner S, Marrone CM, Shaya FT, Hansen J, Lewin J, Blackburn S, Berger M, Dreyer NA. Survey of Real-World Research Workforce, Training, and Education: Report from the DIA Real-World Outcomes Task Force. **Drug Information Journal** 2012; 26:185-191.
64. Dreyer NA, Velentgas P. Registries. In *Pharmacoepidemiology*, Strom B, Kimmel S, Hennessy S, Eds. Fifth edition, John Wiley & Sons Ltd., 2012
65. Oner AF, Dogan N, Gasimov V, Adisasmito W, Coker R, Chan PKS, Lee N, Tsang O, Hanshaoworakul W, Zaman M, Bamgboye E, Swenson A, Toovey S and Dreyer NA: H5N1 Avian Influenza in Children. **Clinical Infectious Disease** 2012; 55:26-32.
66. Gliklich RE, Leavy MB, Velentgas P, Dreyer NA, Tunis SR, Mohr P, Messner DA, Moloney RM, Karkare Su, Dubois RW, Graff JS: Incorporating Stakeholder Perspectives in Developing a Translation Table Framework for Comparative Effectiveness Research. **Journal of Comparative Effectiveness Research** 2012; 1(3):281-292.
67. REGISTER Group (Campbell B, Patrick H, Dreyer NA, Grilli R, Franklin GM, Lee Robin SH, Maddern G, Tunis S, Lyratzopoulos G). International collaboration in the use of registries for new devices and procedures. **British Journal of Surgery** 2012; 99: 744–745.
68. Chan PKS, Lee N, Zaman M, Adisasmito W, Coker R, Hanshaoworakul W, Gasimov V, Oner AF, Dogan N, Tsang O, Phommasack B, Touch S, Bamgboye E, Swenson A, Toovey S, Dreyer N: Determinants of Antiviral Effectiveness in H5N1 Avian Influenza. **Journal of Infectious Disease** 2012; 206: 1359-66.
69. Adisasmito W, Aisyah DN, Aditama TY, Kusriastuti R, Trihono, Suwandono A, Sampurno OD, Prasenohadi, Sapada NA, Mamahit MJN, Swenson A, Dreyer NA, Coker R. Human influenza A H5N1 in Indonesia health care service-associated delays in treatment initiation, **BMC Public Health** 2013; 13:571-577.

70. Dreyer NA, Toovey S, Oner AF, Bamgboye E, Dogan N, Zaman M, Gasimov V, Adisasmito W, Coker R, Chan PKS, Lee N, Tsang O, Hanshaoworakul W, Phommasack B, Touch S, Swenson A, Reddy D. Investigating outbreaks of novel infectious disease: an international case study. **Journal of Clinical Studies** 2013; 5(2):52-53
71. Dreyer NA. Using observational studies for comparative effectiveness: Finding quality with GRACE. **Journal of Comparative Effectiveness Research** 2013; 2(5):413-418.
72. Dreyer NA, Dixon JB, Okerson T, Finkelstein EA, Globe D. Prevalence of Comorbidities and Baseline Characteristics of LAP-BAND AP® Subjects in the Helping Evaluate Reduction in Obesity (HERO) Study. **PLOS One** 2013; 8(11): e78971. doi:10.1371/journal.pone.0078971
73. Mack CD, Dreyer NA, Bosco J, Fabre A. Using real-world evidence to inform decision making. **Chinese Journal of Pharmacoepidemiology** 2014; 24: 17-28.
74. Velentgas P, Dreyer NA, Wu AW. Outcome definition and measurement. In Velentgas P, Dreyer NA, Nourjah P et al., eds. **Developing a Protocol for Observational Comparative Effectiveness Research. A User's Guide**. Rockville, MD: Agency for Healthcare Research and Quality. 2013: Chapter 6, pp. 71-92.
75. Dreyer NA, Velentgas P, Westrich K, Dubois R. The GRACE Checklist for Rating the Quality of Observational Studies of Comparative Effectiveness: A Tale of Hope and Caution. **Journal of Managed Care & Specialty Pharmacy** 2014; 20(3):301-08.
76. Cleeland CS, Mayer M, Dreyer NA, Yim YM, Yu E, SuZ, Mun Y, Sloan JA, Kaufman PA. Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. **Breast** 2014; 23(6): 763-769. doi: 10.1016/j.breast.2014.08.004.
77. Mendelsohn AB, Dreyer NA, Mattox PW, Su Z, Swenson A, Li R, Turner JR, Velentgas P. Characterization of missing data in clinical registry studies. **Therapeutic Innovation & Regulatory Science** 2014; 48(5): 574-582.
78. Dreyer NA. Generating real-world evidence for using drugs and devices: delivering the right approach for the right question. **SCRIP Regulatory Affairs**, March, 2014.
79. Dreyer NA, Duggirala HJ, Samsa G, Stang P, Velentgas P. Registry Design. In Gliklich R, Dreyer N, Leavy M, eds. **Registries for Evaluating Patient Outcomes: A User's Guide**. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014: Chapter 3, pp 47-72.
80. Dreyer NA, Gliklich RE, Sheth N, Trontell AE. Adverse Event Detection, Processing, and Reporting. In Gliklich R, Dreyer N, Leavy M, eds. **Registries for Evaluating Patient Outcomes: A User's Guide**. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014: Chapter 12, pp 277-290.
81. Dreyer NA, Eloff BC, Kirklin JK, Naftel DC, Toovey S. Public-Private Partnerships. In Gliklich R, Dreyer N, Leavy M, eds. **Registries for Evaluating Patient Outcomes: A User's Guide**. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014: Chapter 24, pp 215-230.
82. Dreyer NA, Garner S. Assessing Quality. In Gliklich R, Dreyer N, Leavy M, eds. **Registries for Evaluating Patient Outcomes: A User's Guide**. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014: Chapter 25, pp 231-250.
83. Mack, CD, Su Z, Mendelsohn AB, Dreyer NA. Prevention, examination and treatment of missing data in nonexperimental pharmacoepidemiologic studies. **Chinese Journal of Pharmacoepidemiology** 2015; 24(1): 14-22.
84. Dreyer N, Blackburn S, Hliva V, Mt-Isa S, Richardson J, Jamry-Dziurla A, Bourke A, Johnson R. Balancing the interests of patient data protection and medication safety monitoring in a public-private partnership. **JMIR Medical Informatics** 2015; 3(2):e18 doi:10.2196/medinform.3937
85. Lao W-L, Malone DC, Armstrong EP, Voellinger D, Somers S, Jin J, Dreyer N, Globe D. Effect of adjustable gastric banding on quality of life and weight loss in the Helping Evaluate Reduction in Obesity (HERO) registry study: 2-year analysis **Current Medical Research & Opinion** 2015; 31(8): 1451-1460 Posted on-line July 8, 2015. doi: 10.1185/03007995.2015.1059802 Informa Healthcare, 2015/8/3

86. Dreyer NA, Blackburn SCF, Mt-Isa S, Richardson JL, Thomas S, Laursen M, Zetstra-van der Woude AP, Jamry-Dziurla A, Hliva V, Bourke A, de Jong-van den Berg, LTW. Direct-to-patient research: piloting a new approach to understanding drug safety during pregnancy. **JMIR Public Health and Surveillance** 2015; 1(2); e22. doi:10.2196/publichealth.4939
87. Mack CD, Parmenter L, Brinkley E, Liu L, Dreyer NA. Using enriched real-world research for deeper insights. **Chinese Journal of Pharmacoepidemiology** 2016; 25:27-37
88. Richardson JL, Stephens S, Thomas SHL, Jamry-Dziurla A, de Jong-van den Berg LTW, Zetstra-van der Woude AP, Laursen M, Hliva V, Mt-Isa S, Bourke A, Dreyer NA, Blackburn SCF. An international study of the ability and cost-effectiveness of advertisement methods to facilitate study participant self-enrolment into a pilot pharmacovigilance study during early pregnancy. **JMIR Public Health and Surveillance** 2016; 2(1) e13: 1-10 doi:10.2196/publichealth.5366
89. Dreyer NA, Rodriguez AM. Fast route to evidence development for value in health care. **Current Medical Research and Opinion**. July 11, 2016 DOI: 10.1080/03007995.2016.1203768
90. Dreyer NA. Using Enriched Studies for Post-Approval Evidence Needs” **In Vivo**, July/August 2016
91. NEST Planning Board (Anthony ES, Blake K, Deem M, Dreyer NA, et al.). NEST: Priorities for Effective Early Implementation. A **NEST Planning Board Report- White Paper**. September 2016
92. Dreyer NA, Bryant A, Velentgas P. The GRACE Checklist: A Validated Assessment Tool for High Quality Observational Studies of Comparative Effectiveness. **Journal of Managed Care & Specialty Pharmacy** 2016; 22(10) 1107-1113
93. Courbet T, Dreyer NA, Moussalli R, Wai K. Impact and importance of real world data in Asia: A physician’s perspective. **Value in Health** 2016; 19(7), A852, 201
94. Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn SB, Dreyer NA. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: Review of 3 years of Pharmacovigilance Risk Assessment Committee (PRAC) oversight. **British Journal of Clinical Pharmacology** 2017; 83(4):884-893
95. Urushihara H, Parmenter L, Tashiro S, Matsui, K, Dreyer N. Bridge the Gap: the need for harmonized regulatory and ethical standards for post-marketing observational studies. **Pharmacoepidemiology & Drug Safety** 2017; 26:1299–1306. <https://doi.org/10.1002/pds.4269>, <http://dx.doi.org/10.1002/pds.4269>
96. Bosco JF, Bryant A, Dreyer NA. The Current Biosimilars Landscape and Methodological Considerations for Real-World Evidence Generation. **Value & Outcome Spotlight**, A journal of ISPOR. 2017; 3 (5): 15-18.
97. Dreyer NA. Advancing a framework for regulatory use of real-world evidence: When real is reliable. **Therapeutic Interventions and Regulatory Affairs** 2018; 52(3) 362-368
<http://journals.sagepub.com/doi/full/10.1177/2168479018763591> AWARD WINNER
98. Dreyer N, Franklin P, Haynes KM, Mehta P, Ritchey MB. Direct-to-patient registry and other patient-centric designs. Chapter 4. Gliklich RE, Dreyer NA, Levy M, Christian JB (eds). 21st Century Patient Registries. Registries for Evaluating Patient Outcomes: A User’s Guide. Addendum to Third Edition. (Prepared by L&M Policy Research, LLC, with partners OM1 and QuintilesIMS under Contract No. HHS290201400004C.) AHRQ Publication No. 17(18)-EHC013-EF. Rockville, MD: Agency for Healthcare Research and Quality. March, 2018
99. Christian JB, Dreyer NA. Enriched Studies. Chapter 4.4. Ali AK, Hartzema AG (eds) Post-Authorization Safety Studies of Medicinal Products. The PASS book. Academic Press, 2018
100. Bosco JL, Dreyer, NA, Ali AK. Post-Authorization safety studies for biosimilars and interchangeable biologic products. Chapter 7.1. Ali AK, Hartzema AG (eds) Post-Authorization Safety Studies of Medicinal Products. The PASS book. Academic Press, 2018
101. Girman CJ, Ritchey ME, Zhou W, Dreyer NA. Considerations in Characterizing Real World Data Relevancy and Quality for Regulatory Purposes: A Commentary. **Pharmacoepidemiology & Drug Safety** 2018; Dec 5. Doi: 10.1002/pds.4697
102. Christian JB, Brouwer ES, Girman CJ, Bennett D, Davis KJ, Dreyer NA. Masking in pragmatic trials: who, what and when to blind. **Therapeutic Innovation & Regulatory Science** 2019; Apr;28(4):439-442. doi:10.1002/pds.469
103. Mack C, Meisel P, Herzog M, Oakkar EE, Walden T, Callahan L, Shapre J, Dreyer N, DiFiori J. The Establishment and Refinement of the National Basketball Association Player Injury and Illness Database. **Journal of Athletic Training** 2019; 54(5): 466-471 . <https://doi.org/10.4085/1062-6050-18-19>
104. Dreyer NA, Mack CD, Anderson RB, Wojtyś EM, Herschman EB, Sills A. Lessons on Data Collection and Curation from the NFL Injury Surveillance Program. **Sports Health** 2019; 11(5):440-445. Doi:10.1177/1941738119854759

105. Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J. An Exploratory Analysis of Real-World Endpoints for Assessing Outcomes Among Immunotherapy-Treated Patients with Advanced Non-Small Cell Lung Cancer. **JCO Clinical Care Informatics** 2019; 3:1-15 PMID: 31335166
106. Herzog MM, Mack CD, Dreyer NA, Wikstrom EA, Padua DA, Kocher MS, DiFiori JP, Marshall SW. Ankle Sprains in the National Basketball Association, 2013-14 through 2016-17. **American Journal of Sports Medicine** 2019 Sep;47(11):2651-2658. doi: 10.1177/0363546519864678. Epub 2019 Aug 7
107. Dreyer NA, Macedo AF, Velentgas P. Primary data collection for pharmacoepidemiology. In *Pharmacoepidemiology*, 342-354, Strom B, Kimmel S, Hennessy S, Eds. Sixth edition, John Wiley & Sons Ltd., 2019.
108. Mack C, Christian J, Brinkley E, Warren EJ, Hall M, Dreyer N. When context is hard to come by: external comparators and how to use them. **Therapeutic Innovation & Regulatory Science** Epub November, 2019 DOI: 10.1177/2168479019878672
109. Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. **Pharmacoepidemiology & Drug Safety** 2020; 29:1201-1212. doi.org/10.1002/pds.4932
110. Dreyer NA, Hall M, Christian JB. Modernizing regulatory evidence with trials and real-world studies. **Therapeutic Innovation & Regulatory Sciences** 2020; 54(5), 1112-1115 /doi.org/10.1007/s43441-020-00131-5
111. Laursen M, Hallgreen CE, Dreyer N, Bourke A, Mt-Isa S, Blackburn S. Comparison of electronic self-reported prescription medication use during pregnancy with the national prescription register in Denmark. **Pharmacoepidemiology & Drug Safety** 2020;29:328-336, https://doi.org/10.1002/pds.4937
112. Burcu M, Dreyer NA, Franklin JM, Blum MC, Critchlow CW, Perfetto EM, Zhou W. Real-world evidence to support regulatory decision making for medicines: considerations for external control arms. **Pharmacoepidemiology & Drug Safety** 2020 Mar 11. doi: 10.1002/pds.4975. [Epub] PMID: 32162381
113. Reynolds M, Bourke A, Dreyer NA. Considerations when evaluating real-world data quality in the context of fitness for purpose. **Pharmacoepidemiology & Drug Safety** 2020; 29:1316-1318. DOI: 10.1002/pds.5010
114. Reynolds MW, Christian JB, Mack CD, Hall M, Dreyer NA. Leverage real-world data for COVID-19 research: challenges and opportunities. **Precision Medicine** 2020; 6 (2), June
115. Sheffield KM, Dreyer NA, Murray J, Faries DE, Klopchin. Replication of Randomized Clinical Trial Results Using Real World Data: paving the way for effectiveness decisions. **J Comparative Effectiveness** Published on-line September 13, 2020. <https://www.futuremedicine.com/doi/10.2217/ce-2020-0161>
116. Seeger JD, Davis KJ, Iannacone MR, Zhou W, Dreyer N, Winterstein AG, Santanello N, Gertz B, Berlin JA. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. **Pharmacoepidemiology & Drug Safety** 2020; 29(11):1382-1392. doi.org/10.1002/pds.5141.
117. Cocoros NM, Arlett P, Dreyer NA, Ishiguro C, Iyasu S, Sturkenboom M, Zhou W, Toh, S. The Certainty Framework for assessing real-world data in studies of medical product safety and effectiveness. **Clinical Pharmacology & Therapeutics** 2020; 109:1189-1196., https://doi.org/10.1002/cpt.2045
118. Dreyer NA, Reynolds M, Mack CD, Brinkley E, Petruski-Ivelva N, Hawaldar K, Toovey S, Morris J. Self-reported symptoms from exposure to COVID-19 provide support to clinical diagnosis, triage and prognosis: an exploratory analysis. **Travel Medicine and Infectious Disease** 2020; 38:101909 <https://doi.org/10.1016/j.tmaid.2020.101909>
119. Gliklich RE, Leavy MB, Dreyer NA. Planning a Registry. In *Registries for Evaluating Patient Outcomes: A User's Guide*, Gliklich R, Dreyer N, Leavy M, eds.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. 4th edition, 2020
120. Gliklich RE, Leavy MB, Dreyer NA. Principles of registry ethics, data ownership and privacy. In *Registries for Evaluating Patient Outcomes: A User's Guide*. Gliklich R, Dreyer N, Leavy M, eds. AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. 4th edition, 2020
121. Gliklich RE, Leavy MB, Dreyer NA. Registry Governance. In *Registries for Evaluating Patient Outcomes: A User's Guide*. Gliklich R, Dreyer N, Leavy M, eds.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. 4th edition, 2020

122. Gliklich RE, Leavy MB, Dreyer NA. Data sources for registries. In Registries for Evaluating Patient Outcomes: A User's Guide. Gliklich R, Dreyer N, Leavy M, eds.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. 4th edition, 2020
123. Gliklich RE, Leavy MB, Dreyer NA. Obtaining data and quality assurance. In Registries for Evaluating Patient Outcomes: A User's Guide. Gliklich R, Dreyer N, Leavy M, eds.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. 4th edition, 2020
124. Gliklich RE, Leavy MB, Dreyer NA. Analysis, interpretation and reporting of registry data to evaluate outcomes. In Registries for Evaluating Patient Outcomes: A User's Guide,. Gliklich R, Dreyer N, Leavy M, eds.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. 4th edition, 2020
125. LoCasale R, Pashos CL, Gutierrez B, Dreyer NA, Collins T, Calleja A, Seewald MJ, Plumb JM, Liwing J, Tepie MF, Khosla S. Bridging the gap between RCTs and RWE through endpoint selection. Commentary. **Therapeutic Innovation & Regulatory Science** 2021; 55(1):90-96. <https://doi.org/10.1007/s43441-020-00193-5>
126. Franklin JM , Liaw KL, Iyasu S, Critchlow C, Dreyer N. Real-world evidence to support regulatory decision making: New or expanded medical product indications. **Pharmacoepidemiology & Drug Safety** 2021; 30(6): 685-693. <https://doi.org/10.1002/pds.5222>
127. Dreyer N, Petruski-Ivleva N, Albert L, Mohamed D, Brinkley E, Reynolds M, Toovey S. Identification of a vulnerable group for post-acute sequelae of SARS-CoV-2 (PASC): people with autoimmune diseases recover more slowly from COVID-19. **International Journal of General Medicine** 2021;14 3941–3949. <https://doi.org/10.2147/IJGMS313486>. eCollection 2021
128. Wang CY, Berlin J, Gertz B, Davis K, Li J, Dreyer N, Zhou W, Seeger J, Santanello N, Winterstein A. Uncontrolled Extensions of Clinical Trials and the Use of External Controls - scoping opportunities and methods. **Clinical Pharmacology & Therapeutics** 2021, June 24. doi: 10.1002/cpt.2346.
129. Simon G, Bindman A, Dreyer N, Platt R, Watanabe J, Horberg M, Hernandez A, Califf R. When can we trust real-world data to evaluate new medical treatments? **Clinical Pharmacology & Therapeutics** 2022; 111(1):24-29, 2022/1 doi: 10.1002/cpt.2252
130. Franklin JM, Platt R, Dreyer NA, London AJ, Simon GE, Watanabe JW, Horberg M, Hernandez A, Califf R. When can nonrandomized studies support valid inference regarding effectiveness or safety of new medical treatments? **Clinical Pharmacology & Therapeutics** 2022 Jan;111(1):108-115.doi: 10.1002/cpt.2255. Epub 2021 May 9
131. Kilpatrick RD, Sanchez-Solin O, Alami NN, Johnson C , Fang Y, Wegrzyn LR, Krueger WS, Ye Y, Dreyer N, Gray GC. EpidemiologiCal POPulationN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study. **Infectious Disease and Therapy** 2022; 1-13. <https://doi.org/10.1007/s40121-022-00593-0>
132. Dreyer NA, Reynolds MW, Albert L, Brinkley E, Kwon T, Mack C, Toovey S. How frequent are acute reactions to COVID-19 vaccination and who is at risk? **Vaccine** 2022; 40 (12): 1904-1912 doi.org/10.1016/j.vaccine.2021.12.072
133. Helanterä I, Snyder J, Åsberg A, Cruzado JM, Bell S, Legendre C, Tedesco Silva Jr H, Tedesco Barcelos G, Geissbühler Y, Prieto L, J Christian J, Scalfaro E, Dreyer A. Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence. **Transplant International** 2022; 3:35:10239/ti.2022.10329. eCollection 2022
134. Reynolds MW, Xie Y, Knuth KB, Mack CD, Brinkley E, Toovey S, Dreyer NA. COVID-19 vaccination breakthrough infections in a real-world setting: Using community reporters to evaluate vaccine effectiveness. **Infection and Drug Resistance** 2022; 15:5167–5182
135. Dreyer NA. A community study on COVID-19 vaccine side effects. How community-based insights from patient registries can help us to better understand the side effects of COVID-19 vaccinations. **Pharmaceutical Market Europe**, June 2022: 24-25
136. Dreyer NA. Strengthening evidence-based medicine with real-world evidence. Invited Commentary. **Lancet Healthy Longevity** 2022, 2022 Oct;3(10):e641-e642. doi: 10.1016/S2666-7568(22)00214-8. Epub 2022 Sep 20. PMID: 36150401.
137. Reynolds MW, Secora A, Joules A, Albert L, Brinkley E, Kwon T, Mack C, Toovey S, Dreyer NA. Evaluating real world COVID-19 vaccine effectiveness using a test-negative case-control design. **J Comparative Effectiveness Research** 2022; 2022 Nov;11(16):1161-1172. doi: 10.2217/cer-2022-0069.

138. Sridhara R, Marchenko O, Jiang Q, Barksdale E, Chen, J, Dreyer N, Fashoyin-Aje L, Garrett-Mayer E, Gormley N, Gwise T, Hess L, Mandrekar S, Pignatti F, Rantell K, Raven A, Shen YL, Singh H, Tendler CL, Theoret M, Pazdur R. Evaluation of treatment effect in underrepresented population in cancer trials: Discussion with international regulators. **Statistics in Biopharmaceutical Research** 2023; 15(2): 450-456.. <https://doi.org/10.1080/19466315.2022.2128404>
139. Largent JA, Xie X, Knuth KB, Toovey S, Reynolds MW, Brinkley E, Mack CD, Dreyer NA. Cognitive and other neuropsychiatric symptoms in COVID-19: Analysis of person-generated longitudinal health data from a community-based registry. **BMJ Open** 2023;13:e069118. doi:10.1136/bmjopen-2022-069118
140. Dreyer NA and Mack CD. Tactical considerations for designing real world studies: Fit-for-purpose designs that bridge research and practice. **Pragmatic and Observational Research** 2023;14 101–110
141. Brinkley E, Knuth K, Kwon T, Mack C, Leister Tebbe H, Boa W, Reynolds MW, Dreyer N. Daily COVID-19 symptom assessment over 28 days—findings from a daily direct-to-patient registry of COVID-19 positive patients. **Journal of Patient-Reported Outcomes** 2023; 7 (1), 1-5
142. Sánchez-Soliño O, Kilpatrick RD, Johnson C, Fang Y, Ye Y, Alami NN, Zarish K, Krueger WS, Dreyer N, Gray GC. Longitudinal molecular and serological evidence of SARS-CoV-2 infections and vaccination status: Community-based surveillance study (CONTACT). **Infectious Diseases and Therapy** 2024; <https://doi.org/10.1007/s40121-024-00923-4>
143. Dreyer NA, Knuth KB, Xie Y, Reynolds MW, Mack CD. COVID-19 vaccination reactions and risk of breakthrough infections among people with diabetes: a cohort study derived from community reporters. **JMIR Diabetes** 2024; 9:e45536. doi : [10.2196/45536](https://doi.org/10.2196/45536)
144. Dreyer NA and Blackburn SCF. Power to the people: why person-generated health data is important for pharmacoepidemiology. **American Journal of Epidemiology** 2024; 193(9): 1215-1218 <https://doi.org/10.1093/aje/kwae035>
145. Eckrote MJ, Nielson C, Lu M, Alexander T, Shah RG, Low KW, Zhang Z, Eliazar A, Klesh R, Kress A, Bryant M, Asimwe A, Gatto NM, Dreyer, NA. Linking Clinical Trial Participants to Their U.S. Real-World Data Through Tokenization: A Practical Guide. **Contemporary Clinical Trial Communications** 2024; 41; 101354. ISSN 2451-8654 [www.sciencedirect.com/science/article/pii/S2451865424001017](https://doi.org/10.1016/j.conctc.2024.101354) <https://doi.org/10.1016/j.conctc.2024.101354>
146. Faries D, Gao C, Zhang X, Hazlett C, Stamey J, Yang S, Ding P, Shan M, Sheffield K, Dreyer N: Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence from Comparative Observational Studies through Quantitative Sensitivity Analysis for Unmeasured Confounding. **Pharmaceutical Statistics** 2024; 24(2), e2457
147. Hernandez RK, Critchlow CW, Dreyer N, Lash TL, Reynolds R, Sorensen H, Lange J, Gatto NM, Sobel R, Lai E, Schoonen M, Brown JS, Christian JB, Brookhart MA, Bradbury BD. Advancing Principled Pharmacoepidemiologic Research to Support Healthcare Decision-Making: The Era of Real-world Evidence. **Clinical Pharmacology & Therapeutics** 2025. <https://doi.org/10.1002/cpt.3563>
148. Riskin D, Monda KL, Gagne JJ, Reynolds R, Garan AR, Dreyer N, Muntner P, Bradbury B. Data Reliability: Implementation of accuracy, completeness, and traceability. **JAMA Open** 2025;8(3):e250128. doi:10.1001/jamanetworkopen.2025.0128
149. Foote HP, Hong C, Anwar M, Borentain M, Bugin K, Dreyer N, Fewssel J, Goyal N, Hanger M, Hernandez AF, Hornik, CP, Jackman JG, Lindsay AC, Matheny ME, Ozer K, Seidel J, Stockbridge N, Embi PG, Lindsell CJ. Embracing generative AI in clinical research and beyond: Opportunities, challenges and solutions-JACC: Advances Expert Panel. **JACC Advances** 2025; 4(3): 101593. <https://doi.org/10.1016/j.jacadv.2025.101593>
150. Khozin S, Dreyer NA, Galante D, Liu R, Neumann P, Nussbaum N, O'Shaughnessy J, Patt D, Rimawi M, Rugo H, Tolaney SM, Weiss M, Brufsky A. Real-world evidence acceptability and use in breast cancer treatment decision-making in the US: Call-to-action from a multidisciplinary think tank. **Advances in Therapy** 2025; May 12: <https://doi.org/10.1007/s12325-025-03201-y>
151. Su L, Chen L, Betigeria S, Dreyer N, Gardarsdottir H, Henricks-Stirrup R, Burcu M. Clinical trials with real-world pragmatic elements: A scoping review of use cases and real-world data utilization. **Clinical Pharmacology & Therapeutics** August 19, 2025; <https://doi.org/10.1002/cpt.70033>.

Letters

1. Dreyer NA: Low-level ionizing radiation: Just how great is the cancer risk? **Your Patient and Cancer** 1982; 2(10):74-82.
2. Dreyer NA, Harley N: Response to Johnson by Dreyer and Harley. **American Journal of Public Health** 1983; 73:599-600.
3. Dreyer NA, Harley N: Response to Dr. Johnson. **Health Physics** 1983; 42:814-815.
4. Dreyer NA: Risk evaluation through epidemiology. **Risk Management** 1984; 31(1):50-54.
5. Lanes SF, Dreyer NA, Rothman KJ, Loughlin JE: Motor vehicle accidents and nuclear utility workers. The authors reply. **Journal of Occupational Medicine** 1989; 31:799.
6. Dreyer NA: Bioequivalence of levothyroxine preparations: issues of science, publication, and advertising. **JAMA** 1997; 278(11):897.
7. Loughlin JE, Rothman KJ, Dreyer NA: Lymphatic and hematopoietic cancer mortality in a population attending school adjacent to styrene-butadiene facilities, 1963-1993. Authors Reply. **Journal of Epidemiology and Community Health** 2000; 54:480.
8. Dreyer NA: Relative risk and statistical significance: Epidemiology 101 for lawyers. **Defense Research Institute**, March 19, 2004.
9. Dreyer NA, Garner S: Patient registries, predictive models and optimal care. **JAMA** 2009; 302(24):2662.
10. Adisasmito W, Chan PKS, Lee N, Oner AF, Gasimov V, Zaman M, Bamgboye E, Dogan N, Starzyk K, Dreyer NA, Toovey S Strengthening Observational Evidence for Antiviral Effectiveness in H5N1. **Journal of Infectious Disease** 2011;204: 810-811.
11. Greenacre A, Mack C, Dreyer NA, Pimenta J. Developing a cohort of linked mother-baby pairs to study preterm labor: Harmonizing real-world data from four large united states integrated delivery networks. **Value in Health** 2014;17(3): A183
12. Mack CD, Herzog MM, DiFiori JP, Meisel PL, Dreyer NA, A Second Look at NBA Game Schedules: Response to Teramoto et al. **Journal of Science and Medicine in Sport** 2017,
13. Dreyer NA, Mack CD, Christian JB. Totality of evidence will strengthen our understanding of COVID-19, treatments and recovery. **JAMA Internal Medicine**. On-line Comment, August 3, 2020. <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2768882>
14. Brinkley E. Mack CD, Albert L, Knuth K, Reynolds MW, Toovey S, Dreyer NA. COVID-19 vaccinations in pregnancy: comparative evaluation of acute side effects and self-reported impact on quality of life between pregnant and non-pregnant women in the US. **Am J Perinatology**, 2022 May 6. PMID: 35523212, doi: 10.1055/s-0042-1748158

Selected Scientific Abstracts

1. Dreyer NA: Prospects for epidemiologic studies of low-level ionizing radiation. Society for Epidemiologic Research, June 1980, Minneapolis, MN. **American Journal of Epidemiology** 1980; 112(3):424-425.
2. Dreyer NA: Examining the puzzle of health effects of low-dose ionizing radiation. American Public Health Association, Detroit, MI, October, 1980.
3. Dreyer NA, Kohn HI: Radiation-induced risk of resettling Bikini Atoll. American Public Health Association, Dallas, TX, November, 1983.
4. Loughlin JE, Dreyer NA: Control selection in occupational mortality surveillance. International Epidemiology Association, Helsinki, Finland, August, 1987.
5. Poole C, Dreyer NA, Satterfield MH, Levin L, Rothman KJ: Kidney cancer among petroleum refinery workers. XIIth Scientific Meeting of the International Epidemiological Association, Los Angeles, CA, August, 1990.
6. Wilkinson GS, Dreyer NA: Epidemiology of leukemia among nuclear workers: A quantitative analysis of results from 8 published studies. International Radiation Protection Association Annual Meeting, Montréal, Québec, Canada, May, 1992.
7. Funch D, Dreyer NA, Brickley MG, Walker AM: The validity of case reports in a pharmacoepidemiologic study. 8th International Society for Pharmacoepidemiology, September, 1992.
8. Lanes SL, Birmann BM, Walker AM, Sheffer A, Rosiello R, Dreyer NA: Characterization of asthma management. Pharmacoepidemiology & Drug Safety 1994; 3(1):S31. Presented at the 10th International Conference on Pharmacoepidemiology, Stockholm, Sweden.

9. Sutherland L, Walker AM, Szneke P, Bianchi LA, Dreyer NA, Field LG: Clinical course of ulcerative colitis patients. *Gastroenterology* 1995; 108(4):A924.
10. Loughlin JE, Rothman KJ, Dreyer NA: Mortality from lymphatic and hematopoietic cancer among former students of the Port Neches-Groves High School, 1963-1993. Presented at the Society for Epidemiologic Research, Edmonton, Canada, June 14, 1997.
11. Funch DP, Cecka JM, Sagiv SK, *et al*: Incidence of post-transplant lymphoproliferative disorder among renal transplant patients in the U.S. Presented at the International Society of Pharmacoepidemiology, Boston, MA, August 29, 1999.
12. Velentgas P, Cali C, Dreyer NA, Walker AM, Verberg KM: Risk of myocardial infarction and cardiac death among users of non-steroidal anti-inflammatory medications. **Pharmacoepidemiology & Drug Safety** 2001; 10(1):S241.
13. Velentgas P, Cali C, Diedrick G, Heinen MJ, Walker AM, Verberg K, Dreyer NA: A survey of aspirin use, non-prescription NSAID use and cigarette smoking among users and non-users of prescription NSAIDs: Estimates of the effect of unmeasured confounding by these factors in studies of NSAID use and risk of myocardial infarction. **Pharmacoepidemiology & Drug Safety** 2001; 10(1):S242.
14. Van Den Bos JV, Dreyer NA: Hospital-based outcomes associated with non-traumatic subarachnoid hemorrhage. International Society for Pharmacoeconomics and Outcomes Research. Arlington, VA, May, 2007.
15. Bohn RL, Dreyer NA, Starzyk K, Andrews EB, Singer J. Beyond claims: using patient registries for effectiveness and safety evaluations: **Pharmacoepidemiology & Drug Safety** 2007/7; 16: s77-S78
16. Dreyer NA, Starzyk K, Wilcock K, Toovey S: A global registry for understanding clinical presentation, treatment outcomes, and survival from human avian influenza. Bangkok International Conference on Avian Influenza. 2008 Jan 23; Bangkok: National Center for Genetic Engineering and Biotechnology; p. 155, 2008.
17. Eljovitch L, Dreyer NA, Van Den Bos J, Johnston SC: Under-treatment and outcomes of non-traumatic subarachnoid hemorrhage by hospital volume: a multi-state study. American Heart Association, New Orleans, LA, January, 2008.
18. Bringman S, Dreyer N, Heniford BT, Ramshaw B, Divilio LT, Simpkins DL: Prospective assessment of long-term health outcomes following mesh hernia repair: the international hernia mesh registry. European Hernia Society, Sevilla, Spain, May, 2008.
19. Dreyer NA, Blackburn S, Karwoski C, Stephenson W, Sprafka M: How will FDAAA change our approach to REMS? International Society of Pharmacoepidemiology, Mid-Year Meeting Symposium, Boston, MA, May, 2008.
20. Takemoto SK, Dreyer NA, Faria C, Wang F: Recommendations for the use of patient registry data as a complement to randomized clinical trials. International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May, 2008.
21. Dreyer NA, Berger M, Sullivan S, LeLorier J: Are good practices principles for observational comparative effectiveness studies needed? International Society for Pharmacoeconomics and Outcomes Research, Toronto, Canada, May, 2008.
22. Adisasmito W, Zaman M, Chan P, Lee N, Gasimov V, Aghayev FF, Oner A, Bamgboye E, Dogan N, Starzyk K, Layton A, Coker R, Toovey S, Dreyer N: Human avian influenza: development of a shoe-leather approach to evaluating treatment effectiveness. International Society of Pharmacoepidemiology, Providence, RI, August, 2009.
23. Zhao S, Dreyer NA, Cole A, Stemhagen A, Feltelius N, Haas J: Can registries deliver? The methods and use of registries for biologics. **Pharmacoepidemiology & Drug Safety** 2009; 18:S27.
24. Dreyer NA, Rubino A, L'Italien GJ, Schneeweiss S: Developing good practice guidance for non-randomized studies of comparative effectiveness: a workshop on quality and transparency. **Pharmacoepidemiology & Drug Safety** 2009;18:S123.
25. Avian Influenza Expert Group (Adisasmito W, Zaman M, Chan P, Lee N, Gasimov V, Aghayev FF, Oner A, Bamgboye E, Dogan N, Toovey S, Dreyer N): First results from an avian influenza registry. American Society for Microbiology 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September, 2009.
26. Adisasmito W, Latief K, Seitzman R, Layton A, Toovey S, Dreyer N: Avian influenza in Indonesia: a descriptive analysis – Indonesia. 2005-2009. 5th TEPHINET Southeast Asia and Western Pacific Bi-Regional Scientific Conference, Seoul, Korea, November, 2009.

27. Adisasmito W, Chan PKS, Lee N, Oner AF, Gasimov F, Zaman M, Bamgboye E, Dogan N, Coker R, Toovey S, Dreyer NA: Improving the odds of surviving H5N1. International Symposium on Respiratory Viral Infections, Taipei, Taiwan, March, 2010.
28. Zaman M, Chan PKS, Lee N, Oner AF, Gasimov V, Bamgboye E, Dogan N, Toovey S, Dreyer NA: The avian flu registry: How we got it, and what it tells us. ChestCON 2010, 9th Biennial International Conference, Pakistan Chest Society, Bhurbon, Murree Pakistan, March, 2010.
29. Oner AF, Bamgboye E, Gasimov V, Zaman M, Chan PKS, Lee N, Dogan N, Adisasmito W, Toovey S, Dreyer NA: Avian influenza infections in children: symptoms & treatment. European Society for Paediatric Infectious Diseases, Nice, France, May, 2010.
30. Kaufman PA, Dreyer NA, Mayer M, Sloan JA, Chung CY, Sing A, Yim YM, Yu E, Mathias SD, Cleeland CS: Capturing breast cancer patients experience beyond disease progression: implementation of a patient-reported outcome (PRO) substudy in the VIRGO metastatic breast cancer observational cohort study. American Society of Clinical Oncology, Chicago, June, 2010.
31. Dreyer, N. Generating evidence for decision making. *Am J Epidemiol* 2010; 171(Suppl):S158-S165.
32. Williams R, Fu Q, Danis R, Dreyer N. Anti-VEGF treatment patterns among age-related macular degeneration patients in U.S. clinics: the PRACTICE study. 2010 Joint Meeting of the American Academy of Ophthalmology and the Middle East Africa Council of Ophthalmology, Chicago, IL, October, 2010.
33. Adisasmito W, Chan PKS, Lee N, Oner AF, Gasimov V, Aghayev F, Zaman M, Bamgboye E, Dogan N, Coker R, Starzyk K, Dreyer NA, Toovey S: Global patient registry for influenza A/ H5N1: Strengthening results using multiple imputation. XII International Symposium on Respiratory Viral Infections, Rome, Italy, 13-16 March 2011.
34. Dreyer NA, Toovey S, Adisasmito W, Bamgboye, Chan PKS, Coker R, Dogan N, Gasimov V, Hanshaoworakul W, Lee N, Oner AF, M Zaman: Global patient registry for A/H5N1: A modest success story. XII International Symposium on Respiratory Viral Infections, Rome, Italy, 13-16 March 2011.
35. Dreyer, NA, Toovey S, Adisasmito W, Bamgboye E, Chan PKS, Coker R, Dogan N, Gasimov V, Hanshaoworakul W, Lee N, Oner AF, Zaman M. Handling missing data in prospective registries. Agency for Healthcare Research & Quality Comparative Effectiveness Research Methods Symposium, June 6-7 2011.
36. Jalbert JJ., Chen CY, Schneeweiss S, Hammill BG, Dreyer NA, Delaney JAC, Gerhard T, Setoguchi. Database Linkage and Methodological Issues in Comparative Effectiveness Research of Medical Devices vs. Medications: Lessons from an Ongoing Project. **Pharmacoepidemiology & Drug Safety** 2011; 20: S1–S364
37. Swenson AJ, Mack C, Dreyer N, Adisasmito W, Bamgboye E, Chan PKS, Coker R, Dogan N, Gasimov V, Hanshaoworakul W, Lee N, Oner AF, Toovey S, Zaman M. Multiple Imputation: Application to a Global Avian Influenza Registry. Int'l Conference on Pharmacoepidemiology & Therapeutic Risk Management. **Pharmacoepidemiology and Drug Safety** 2011; 20: S1–S364
38. Adisasmito W, Chan PKS, Lee N, Oner AF, Gasimov V, Zaman M, Bamgboye E, Dogan N, Coker R, Hanshaoworakul W, Swenson A, Toovey S, Dreyer NA. Effectiveness of Oseltamivir Treatment in Human Influenza A (H5N1) Infections: An Updated Analysis. The Fourth European Scientific Working group on Influenza Conference. Malta, 11-14 Sep 2011
39. Zaman M, Adisasmito W, Bamgboye E, Coker R, Gasimov V, Hanshaoworakul W, Oner A, Swenson A, Dreyer N, Toovey S. Clinical Characteristics & Treatment Effectiveness in Possible Human Cases of H5N1. The Fourth European Scientific Working group on Influenza Conference. Malta, 11-14 Sep 2011
40. Dixon JB, Dreyer N, Finkelstein EA, Su Z, Globe D, Okerson T. Assessing real-world European patient profiles in the Helping Evaluate Reduction in Obesity (HERO) study. EuroPrevent, Dublin, Ireland, 3 May 2012
41. Zaman M, Adisasmito W, Hanshaoworakul W, Oner AF, Chan PKS, Lee N, Tsang O, Gasimov V, Bamgboye E, Dogan N, Coker R, Swenson A, Dreyer NA, Toovey S. Macrolides and Anti-Inflammatory Agents in the Treatment of Avian Influenza (H5N1). XIV International Symposium on Respiratory Viral Infections, 23 – 26 March 2012, Istanbul, Turkey
42. Dixon JB, Finkelstein EA, Dreyer N, Menon V, Globe D, Okerson T. Helping Evaluate Reduction in Obesity: Characterizing Patients Who Choose LAP-BAND in the HERO Observational Study. Poster presentation at: the 29th Annual Meeting of the American Society for Metabolic and Bariatric Surgery. June 17-22, 2012; San Diego, CA

43. Dreyer N, Leavy MB, Velentgas P. Studies to inform decision-making: the need for a two-phase approach to assessing quality and appropriateness. [abstract]. ISPOR 5th Asia-Pacific Conference, 2-4 September 2012, Taipei, Taiwan
44. Dixon JB, Okerson T, Burk C, Rui S, Ng-Mak C, Globe D, Dreyer NA. One Year Change in Metabolic Syndrome Components in the Helping Evaluate Reduction in Obesity (HERO) study. European Association for the Study of Diabetes. 2-5 October, 2012, Berlin, Germany
45. Dixon JB, Okerson TE, Burk CT, Shi R, Ng-Mak DS, Globe D, Dreyer NA. One Year Evaluation of Metabolic Syndrome in the Helping Evaluate Reduction in Obesity (HERO) Study. Canadian Journal of Diabetes 2012 (October);36(5) S:68
46. Kaufman PA, Mayer M, Dreyer NA, Yim YM, Yu E, Su Z, Mun Y, Sloan JA, Cleeland CS. Patient-reported outcomes in patients with metastatic breast cancer from the VIRGO observational cohort study. ASCO Breast Cancer Symposium, Sep 13 - 15, 2012, San Francisco, CA.
47. Dreyer NA, Velentgas P, Westrich K, Dubois, RW. There but for GRACE? A Validated Screening Tool for Quality Observational Studies of comparative effectiveness. [Winner, best poster award] ISPOR, May 26, 2013, New Orleans, LA
48. Gliklich, RE, Dreyer NA, Leavy MB, Khurana L, Mattox P, Berliner E, Kremer JM, Pappa D. Nesting Studies within Patient Registries. Poster, AcademyHealth Annual Research Meeting. June 2013. Baltimore, MD
49. Toovey S, Zaman M, Oner AF, Adisasmito W, Coker R, Bamgboye EL, Chan PKS, Hanshaworakul W, Lee N, Touch S, Phommasack B, Tsang O, Swenson A, Dreyer NA. Recognizing true H5N1 infections during confirmed outbreaks. Options for the Control of Influenza. Cape Town, South Africa, September 5-13, 2013
50. Dreyer NA, Velentgas P, Westrich K, DuBois R: Using the GRACE Checklist for Quality in Observational Research. DIA, June, 2014, San Diego, CA
51. Dreyer NA. Public-Private Partnerships: An Innovative Strategy for Patient Registries, DIA, June, 2014, San Diego, CA
52. Richardson JL Stephens S, Thomas SHL, Latos-Bielenska A, Jamry-Dziurla A, de Jong-van den Berg LTW, Zetstra-van der Woude P, Laursen M, Dreyer N, Hliva V, Mt-Isa S, Blackburn SCF. Participant Recruitment to the PROTECT Pregnancy Study: a Non-interventional, Prospective Study of Self-Reported Medication Use and Obstetric Outcomes as Provided by a Cohort of Pregnant Women. 2nd International OTIS-ENTIS Conference at The Hospital for Sick Children, Toronto, Canada September 19–21, 2014. Birth Defects Res Part A: Clinical Molecular Teratology 2014;100 (7): s. 548-549.
53. Dreyer NA, Bryant A, Su Z, Velentgas P. Use of the GRACE checklist for rating the quality of observational comparative effectiveness research. **Value in Health** 2014; 7(17): A732.
54. Noh E, Dreyer NA, Ahn J, Alshammari TM, Ritchey ME, Layton JB, Caffrey AR. Guidelines and Recommendations for Comparative Effectiveness Research (CER) Methods: International Assessment and Exchange. International Society of Pharmacoepidemiology, Taipei, Taiwan. **Pharmacoepidemiology & Drug Safety** 2014; 23(s1): 205.
55. Engel P, Bulliard M, Parmenter L, Starzyk K, Dreyer N. Lessons learned on the design of European post authorisation safety studies (PASS): Review of 18 Months of PRAC Oversight. **Pharmacoepidemiology & Drug Safety** 2014; 23(S1): 330-331.
56. Richardson JL, Holt, SHL Thomas, Stephens S, Jamry A, Latos-Bielenska A, Zetstra-van der Woude PA, de Jong-van den Berg L,TW, Laursen M, Mt-Isa S, Bigouret-Hliva V, Dreyer NA, Blackburn, SCF. Internet advertisement methods provide highest levels of recruitment to a pilot study of self-reported medication use and pregnancy outcomes. **Pharmacoepidemiology & Drug Safety** 2014; 23(S1): 312-13.
57. Dreyer NA, Mt-Isa S, Richardson JL, Laursen M, Zetstra-van der Woude PA, de Jong-van den Berg L, Jamry-Dziurria A, Thomas SHL, Blackburn SCF. Direct-from-patient information on medication Use: PROTECT pregnancy study results. **Pharmacoepidemiology & Drug Safety** 2014; 23(S1): 305.
58. Francisco G, Bandari D, Adams Manack A, Dreyer N, Velentgas P, Esquenazi A. Utilization Patterns and Effectiveness of OnabotulinumtoxinA for the Treatment of Spasticity: The Adult Spasticity International Registry on BOTOX Treatment (ASPIRE) Study Methods. Poster. 9th World Congress of the International Society of Physical and Rehabilitation Medicine (ISPRM). June 19-23, 2015. Berlin, Germany
59. Dreyer NA, Mt-Isa S, Jamry A, Blackburn S, Bourke A. The feasibility and comparison of self-reported data: a pilot study in pregnancy. EUROMediCAT European Conference “Safety of Medication Use in Pregnancy”, Poznan, Poland, 2-4 February 2015

60. Dreyer NA, Bryant A, Velentgas P, Su Z. Best methods to get your comparative effectiveness paper cited: how GRACE helps. Poster presented at the International Society of Pharmacoepidemiology August 24-26, 2015. **Pharmacoepidemiology & Drug Safety** 2015; 24: 360-361
61. Dreyer NA, Mt-Isa S, Richardson JL, et al. Direct-to-patient Research: The Future of Pharmacovigilance? **Pharmacoepidemiology and Drug Safety** 2015;24:268-269
62. Mack CD, Franke K, McCarron O, Bryant A, Jablonski R, Barboza M, Dreyer NA. NFL Injury Surveillance and Analytics: Improving Data Collection through Use of Electronic Medical Records. **Pharmacoepidemiology & Drug Safety** 2015;24:523.
63. Mack CD, McNeil A, Parmenter L, Davis K, Dreyer NA. Hybrid prospective studies: combining existing and new data sources to achieve research goals. **Pharmacoepidemiology & Drug Safety** 2015;24:544-545.
64. Bosco JL, Dreyer NA, Neyerapally G, Brown JS. Generating real-world safety and effectiveness for biosimilars: current issues and methodological considerations. **Pharmacoepidemiology & Drug Safety** 2015;24:416-417
65. Bryant A, Mendelsohn AB, Viswanathan S, Dreyer NA. What impacts the quality of comparative effectiveness research: A classification and regression tree analysis using the GRACE checklist. **Value in Health** 2016; 19(3), A277, Elsevier, 2016/5/1
66. Mack C, Parmenter L, Velentgas P, Franke K, Jablonski R, Dreyer NA. Delivering actionable results for observational studies through rapid evaluation processes. **Value in Health** 2016; 19(3), A85, Elsevier, 2016/5/1
67. Brinkley E, Mack CD, Christian JB, Dreyer NA. Developing research partnerships with health networks for real-world evidence generation. Abstract. DIA Annual Meeting. Chicago, IL June 2017.
68. Brinkley E, Midha Y, Lobeck F, Dreyer N, Lang K, Christian JB. Optimizing Global Protocols for Local Implementation Using Real-World Data: A Multi-Country Approach in Ulcerative Colitis. **Pharmacoepidemiology & Drug Safety** 2017; 26:561
69. Ritchey ME, Lystig TC, Velentgas P, Brouwer ES, Canos DA, Lund J, Berlin JA, Dreyer NA. Fit-for-purpose non-traditional RCTs. What will it take to convince a skeptical community? International Society of Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] **Pharmacoepidemiology & Drug Safety** 2017 Aug; 26(Suppl 2):29. doi: 10.1002/pds
70. Brinkley E, Midha Y, Lobeck F, Dreyer NA, Lang K, Christian JB. Using real-world data to support protocol optimization: a multi country approach in ulcerative colitis. **Value in Health** 2017; 20 (5), A319-A319
71. Bourke A, Laursen M, Dreyer N, Erikstrup Hallgreen C, Blackburn S. Can patients accurately report their drugs? A comparison of self-reported medication with a national register in Denmark in a subset of the PROTECT Pregnancy Cohort. Poster. International Society of Pharmacoepidemiology & Risk Management, 2018 annual conference. **Pharmacoepidemiology & Drug Safety** 2018; 27 (2):87
72. Mack C, Herzog M, Oakkar E, Shiue K, Meisel P, Dreyer NA, DiFiori J. EHR-driven Evidence for Health and Wellness Research: Lessons from the NBA. International Society of Pharmacoepidemiology & Drug Safety, 2018 Annual Conference. **Pharmacoepidemiology & Drug Safety** 2018; 27 (2):329-330
73. Wang CY, Gretenkord J, Seeger JD, Davis KJ, Iannacone MR, Zhou W et al. Frequency and characteristics of uncontrolled long-term extensions to randomized controlled trials. **Pharmacoepidemiology & Drug Safety** 2020; 29:373.
74. Herzog MM, Marshall SW, Dreyer NA, Mack DC. Lookback period definition in electronic medical record research. **Pharmacoepidemiology & Drug Safety** 2020; 29:405-406.
75. Dreyer N, Petruski-Ivleva N, Albert L, Brinkley E, Mack C, Reynolds M. COVID-19 symptom severity among smokers: Insights from a direct-to-community registry. **Pharmacoepidemiology & Drug Safety** 2021: 187
76. Petruski-Ivleva N, Joules A, Warner M, Long P, Cooper A, Dreyer NA. Collider bias in COVID-19 studies: explaining the smoking paradox. **Pharmacoepidemiology & Drug Safety** 2021; 30:103-10
77. Dreyer N, Petruski-Ivleva N, Albert L, Brinkley E, Mohamed D, Mack C, Reynolds C. Persistence of COVID-19 symptoms 90 days post-acute infection: insights from a community-based registry. **Pharmacoepidemiology & Drug Safety** 2021; 30:26
78. Weiss L, Dohse H, Teltsch DY, Dreyer NA, Cai J, Gardarsdottir. From the individual through the health system and back: the interdisciplinary promise and challenges of digital epidemiology for improved outcomes. **Pharmacoepidemiology & Drug Safety** 2021; 30:7
79. Bourke A, Petruski-Ivleva, Albert L, Dreyer NA. Comparing two geographic sources of patient-generated health data in a COVID-19 registry. **Pharmacoepidemiology & Drug Safety** 2021; 30:178-179

80. Bratton EW, Petruski-Ivleva N, Albert L, Dreyer NA. Women of reproductive age in the COVID-19 active research experience (CARE) registry. **Pharmacoepidemiology & Drug Safety** 2021; 30:399
81. Brinkley E, Mack C, Petruski-Ivleva N, Reynolds M, Bourke A, Hawalder K, Dreyer NA. Patients tell all: using a direct-to-patient community registry to understand patient burden of COVID-19. **Pharmacoepidemiology & Drug Safety** 2021; 30:98
82. Kosta K, Hall M, Reich C, Dreyer NA, Reynolds M. Old methods and new data: a near real-time plan for vaccine surveillance and signal detection in COVID-19. **Pharmacoepidemiology & Drug Safety** 2021; 30:284
83. Herzog MM, Marshall SW, Dreyer NA, Mack CD. Methodologic considerations for quantifying prior injury studies of injury recurrence. International Olympic Committee poster. 2021, **British Journal of Sports Medicine** 55 (Suppl 1), A157-A157, 2021
84. Herzog MM, Mack CD, Dreyer NA, Winstrom EA, Padua DA, Kocher MS, Marshall S. Association between ankle sprain history and ankle sprain incidence in National Basketball Association Games. International Olympic Committee poster, 2021, **British Journal of Sports Medicine** 55 (Suppl 1), A43-A44, 2021
85. Brinkley E, Mack CD, Albert L, Knuth K, Reynolds MW, Toovey S, Dreyer NA. COVID-19 vaccinations in pregnancy: a comparative evaluation of acute side effects and impact on quality of life between pregnant and non-pregnant women in the US. Poster, 2021 International Society for Influenza and other Respiratory Virus Diseases – World Health Organization Conference. 19-21 October 2021
86. Reynolds M, Xie Y, Knuth K, Brinkley E, Kwon T, Mack C, Dreyer N. Hospitalizations after COVID-19 Vaccination: Self-reported patient characteristics. **Pharmacoepidemiology & Drug Safety** 2022; 31: 611-612
87. Knuth K, Reynolds MW, Brinkley E, Xie Y, Kwon T, Mack CD, Dreyer NA. Diabetics report fewer side effects from COVID-19 vaccination than non-diabetics in the US. **Pharmacoepidemiology & Drug Safety** 2022; 31, 614.
88. Xie Y, Reynolds MW, Knuth K, Brinkley E, Kwon T, Mack CD, Dreyer N. What distinguishes people who experience side effects of COVID-19 vaccines from those who don't? **Pharmacoepidemiology & Drug Safety** 2022; 31, 622.,
89. Largent J, Xie Y, Reynolds MW, Knuth KB, Brinkley E, Mack CD, Toovey S, Dreyer NA. COVID brain: the CARE experience. **Pharmacoepidemiology & Drug Safety** 2022; 31, 608.
90. Largent J, Xie Y, Reynolds MW, Knuth KB, Brinkley E, Mack CD, Toovey S, Dreyer NA. Cognitive and other neuropsychiatric symptoms in COVID-19: Analysis of person-generated health data from a community-based registry. **Pharmacoepidemiology & Drug Safety** 2022; 31, 607
91. Sanchez-Solino O, Kilpatrick RD, Johnson C, Fang Y, Zarish K, Ye Y, Dreyer NA, Gray GC. EPH66 Epidemiological Population Study of Sars-Cov-2 in Lake County, Illinois: Contact: Health-Related Quality of Life Assessment. **Value Health** 2023; Jun; 26(6): S176
92. Eckrote MJ, Nielson CM, Lu M, Alexander T, Shah, RG, Low KW, Zhang Z, Eliazar A, Flesh R, Kress A, Bryant M, Asimwe A, Gatto NM, Dreyer NA. Linking clinical trials participants to the US real-world data through tokenization. A practice guide. **Pharmacoepidemiology & Drug Safety**, 2024; 33, 612-613.